Arca
Skip to content
Tools
Tools

Label Changes: Camzyos (mavacamten)

A drug's label (its prescribing information) is revised many times after approval: new warnings, new uses, new doses. DailyMed keeps every version. Pick a drug to see them all and what changed between any two.

Every version of the Camzyos label DailyMed has published, from Myokardia, Inc., and what changed between any two of them, section by section. Current label on DailyMed.

  • Versions on DailyMed: 9
  • Sections changed, version 8 to 9: 18

What changed from version 8 to version 9

May 1, 2025 to Oct 12, 2026, as published on DailyMed. Added text is underlined in green, removed text struck through in red.
  1. Indications and usageChanged · 10 words added, 10 removed
  2. Dosage and administrationChanged · 242 words added, 54 removed
  3. Dosage forms and strengthsChanged · 34 words added, 15 removed
  4. ContraindicationsChanged · punctuation or symbols only
  5. Warnings and precautionsChanged · punctuation or symbols only
  6. Adverse reactionsChanged · 67 words added, 2 removed
  7. Drug interactionsChanged · 42 words added, 46 removed
  8. Use in specific populationsChanged · 85 words added, 1 removed
  9. OverdosageChanged · 2 words added, 11 removed
  10. DescriptionChanged · 17 words added, 14 removed
  11. Clinical pharmacologyChanged · 269 words added, 1 removed
  12. Clinical studiesChanged · 575 words added, 22 removed
  13. How suppliedChanged · 8 words added
  14. Medication guideChanged · 27 words added, 15 removed
  15. CAMZYOS 1 mg LabelChanged · 20 words added, 20 removed
  16. CAMZYOS 5 mg LabelChanged · 3 words added, 3 removed
  17. CAMZYOS 10 mg LabelChanged · 3 words added, 3 removed
  18. CAMZYOS 15 mg LabelNew section · 50 words added

Indications and usage

Changed10 words added, 10 removed
1 INDICATIONS AND USAGE
CAMZYOS® is indicated for the treatment of adults withand symptomaticpediatric Newpatients Yorkweighing Heart30 Associationkg (NYHA)or classmore II-IIIwith symptomatic obstructive hypertrophic cardiomyopathy (HCM) to improve functional capacity and symptoms.

Dosage and administration

Changed242 words added, 54 removed
1 unchanged line
2.1 Initiation, Maintenance, and Interruption of Treatment
Confirm absence of pregnancy and usage of effective contraception in females of reproductive potential [see Warnings and Precautions (5.4) and Use in Specific Populations (8.1, 8.3)].
Initiation or up-titration of CAMZYOS in patients with LVEF <55% is not recommended.
Initiation Dosage in Adult Patients The recommended starting dose is 5 mg orally once daily without regard to food; allowable subsequent doses with titrationtitrations are 2.5 mg, 5 mg, 10 mg, or 15 mg orally once daily. The maximum recommended dose is 15 mg orally once daily.
Patients may develop heart failure while taking CAMZYOS. Regular LVEF and Valsalva left ventricular outflow tract (LVOT) gradient assessment is required for careful titration to achieve an appropriate target Valsalva LVOT gradient, while maintaining LVEF ≥50% and avoiding heart failure symptoms (see Figure 1 and Figure 23).
Daily dosing takes weeks to reach steady-state drug levels and therapeutic effects, and genetic variation in metabolism and drug interactions can cause large differences in exposure [see Boxed Warning, Contraindications (4), Warnings and Precautions (5.2), Drug Interactions (7.1) and Clinical Pharmacology (12.3)].
When initiating or titrating CAMZYOS, first consider LVEF then consider the Valsalva LVOT gradient and patient clinical status to guide appropriate CAMZYOS dosing. Assessment of post-exercise LVOT gradient may be considered in symptomatic patients with normal or near normal Valsalva gradients (approximately 30 mmHg) prior to initiating treatment with CAMZYOS. Follow the algorithms for Initiation (Figure 1) and Maintenance (Figure 23) for appropriate CAMZYOS dosing and monitoring schedules.
If LVEF <50% while taking CAMZYOS, interrupt treatment. Follow the algorithm for Interruption (Figure 34) for guidance on interrupting, restarting, or discontinuing CAMZYOS. If interrupted at 2.5 mg, either restart at 2.5 mg or discontinue permanently.
Figure 1: Initiation Phase
Figure 1: Initiation Phase for Adult Patients
Initiation Dosage in Pediatric Patients
The recommended starting dose is
• 5 mg orally once daily for pediatric patients weighing greater than or equal to 45 kg. • 2.5 mg orally once daily for pediatric patients weighing 30 kg to less than 45 kg.
CAMZYOS was not studied in pediatric patients weighing less than 30 kg.
CAMZYOS is taken orally once daily without regard to food; allowable subsequent doses with titrations are 1 mg, 2.5 mg, 5 mg, 10 mg, or 15 mg. The maximum recommended dose is 15 mg orally once daily.
Follow the algorithms for Initiation (Figure 2) and Maintenance (Figure 3) for appropriate CAMZYOS dose adjustment and monitoring schedules in pediatric patients.
If LVEF <50% while taking CAMZYOS, interrupt treatment. Follow the algorithm for Interruption (Figure 4) for guidance on interrupting, restarting, or discontinuing CAMZYOS.
Figure 2: Maintenance Phase
Figure 2: Initiation Phase for Pediatric Patients
Maintenance and Interruption of Treatment in Adult and Pediatric Patients
Figure 3: Maintenance Phase for Adult and Pediatric Patients
Figure 34: Treatment Interruption at Any Clinic Visit if LVEF <50% for Adult and Pediatric Patients
Delay dose increases when there is intercurrent illness (e.g., serious infection) or arrhythmia (e.g., atrial fibrillation or other uncontrolled tachyarrhythmia) that may impair systolic function. Consider interruption of CAMZYOS in patients with intercurrent illness [see Warnings and Precautions (5.1)].
3 unchanged lines
2.2 Concomitant Administration of Weak to Moderate CYP2C19 or Moderate to Strong CYP3A4 Inhibitors
Initiate CAMZYOS at the recommended starting dosage of 5 mg orally once daily in patients who are on stable therapy with a weak CYP2C19 inhibitor or a moderate CYP3A4 inhibitor (see Figure 1 for adults and Figure 2 for pediatric patients).
In patients who are on stable therapy with a moderate CYP2C19 inhibitor or a strong CYP3A4 inhibitor, initiate CAMZYOS at 2.5one mgdose orallybelow oncethe dailyrecommended starting dose. Interrupt CAMZYOS treatment if Valsalva LVOT gradient is <20 mm Hg at Week 4 or Week 8 if the patient is on the lowest dose. Treatment may be resumed after 4 weeks at 2.5that mgdose once daily if LVEF is ≥50%. If treatment is resumed atby Week 12, recheck clinical status, Valsalva LVOT gradient and LVEF in 4 weeks, and maintain the current dose for the next 8 weeks unless LVEF is <50%.
In patients who initiate a weak to moderate CYP2C19 inhibitor or a moderate to strong CYP3A4 inhibitor, reduce dosage of CAMZYOS to the next lower daily (mg) dose level (i.e., 15 mg to 10 mg; 10 mg to 5 mg; or 5 mg to 2.5 mg; or 2.5 mg to 1 mg [pediatric]). Schedule clinical and echocardiographic assessment 4 weeks after inhibitorthe initiation of a CYP2C19 or CYP3A4 inhibitor, and do not up-titrate to the next higher daily (mg) dose level of CAMZYOS until 12 weeks after inhibitor initiationlater. Avoid initiation of concomitant weak to moderate CYP2C19 and moderate to strong CYP3A4 inhibitors in patients who are on stable treatmentthe withlowest 2.5recommended mgdose of CAMZYOS because a lower CAMZYOS once-daily dose is not available [ see Dosage and Administration (2.1), Drug Interactions (7.1) ] .
For short-term use (e.g., 1 week), interrupt CAMZYOS for the duration of treatment with a weak to moderate inhibitor of CYP2C19 or a moderate to strong inhibitor of CYP3A4. MavacamtenCAMZYOS may be reinitiated at the previous dose immediately on discontinuation of concomitant therapy.

Dosage forms and strengths

Changed34 words added, 15 removed
3 DOSAGE FORMS AND STRENGTHS
CAMZYOS is available as capsules imprinted with the strength and “Mava” in the following strengths:
CAMZYOS capsules contain white to off-white powder. The opaque capsule cap is imprinted with the strength, and the white opaque capsule body is imprinted with “Mava”. Available strengths include:
•1 mg – white cap
•2.5 mg – light purple cap
3 unchanged lines

Contraindications

Changedpunctuation or symbols only
1 unchanged line
CAMZYOS is contraindicated with concomitant use of:
• Strong CYP2C19 inhibitors [see Warnings and Precautions (5.2) , Drug Interactions (7.1) ]
•Moderate to strong CYP2C19 inducers or moderate to strong CYP3A4 inducers [see Warnings and Precautions (5.2), Drug Interactions (7.1)]

Warnings and precautions

Changedpunctuation or symbols only
1 unchanged line
5.1 Heart Failure
CAMZYOS reduces systolic contraction and can cause heart failure or significantly reduce ventricular function. Patients who experience a serious intercurrent illness (e.g., serious infection) or arrhythmia (e.g., atrial fibrillation or other uncontrolled tachyarrhythmia) are at greater risk of developing systolic dysfunction and heart failure [see Clinical Trial Experience (6.1) ] .
Assess the patient’s clinical status and LVEF prior to and regularly during treatment and adjust the CAMZYOS dose accordingly [see Dosage and Administration (2.1)]. New or worsening arrhythmia, dyspnea, chest pain, fatigue, palpitations, leg edema, or elevations in N-terminal pro-B-type natriuretic peptide (NT-proBNP) may be signs and symptoms of heart failure and should also prompt an evaluation of cardiac function.
15 unchanged lines

Adverse reactions

Changed67 words added, 2 removed
4 unchanged lines
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
The safety of CAMZYOS was evaluated in EXPLORER-HCM, a Phasephase 3, double-blind, randomized, placebo-controlled trial [see Clinical Studies (14)]. Of the 251 adults with obstructive HCM, 123 patients were treated with CAMZYOS 2.5-15 mg daily and 128 were treated with placebo. CAMZYOS-treated patients had a median duration of exposure of 30 weeks (range: 2-40 weeks).
Syncope (0.8%) was the only adverse drug reaction leading to discontinuation in patients receiving CAMZYOS.
Adverse reactions occurring in >5% of patients and more commonly on CAMZYOS than on placebo were dizziness (27% vs. 18%) and syncope (6% vs. 2%).
The safety of CAMZYOS in patients was further evaluated in VALOR-HCM, a Phasephase 3, double-blind, randomized, placebo-controlled trial [see Clinical Studies (14)]. Of the 112 adults with symptomatic obstructive HCM, 56 patients were treated with CAMZYOS 2.5-15 mg daily and 55 were treated with placebo. CAMZYOS-treated patients had a median duration of exposure of 17 weeks (range: 3-19 weeks).
There were no new adverse reactions identified in VALOR-HCM.
The safety of CAMZYOS in pediatric patients (≥ 35 kg) was evaluated in SCOUT-HCM, a phase 3, double-blind, randomized, placebo-controlled trial [see Clinical Studies (14)]. Of 44 patients with symptomatic obstructive HCM, 23 patients were treated with CAMZYOS 1.0-15 mg daily and 21 patients were treated with placebo.
There were no new adverse reactions compared to those identified in adult studies.
Effects on Systolic Function
1 unchanged line

Drug interactions

Changed42 words added, 46 removed
12 unchanged lines
Clinical Impact | Concomitant use with a weak CYP2C19 inhibitor or a moderate CYP3A4 inhibitor increases mavacamten exposure, which may increase the risk of adverse drug reactions [see Warnings and Precautions (5.2)].
Prevention or Management | Initiate CAMZYOS at the recommended starting dosage of 5 mg orally once daily in patients who are on stable therapy with a weak CYP2C19 inhibitor or a moderate CYP3A4 inhibitor (see Figure 1 for adults and Figure 2 for pediatric patients). Reduce dose of CAMZYOS to the next lower daily (mg) dose level ([i.e., 15 mg to 10 mg, 10 mg to 5 mg, or 5 mg to 2.5 mg, or 2.5 mg to 1 mg (pediatric)] in patients who are on CAMZYOS treatment and intend to initiate a weak CYP2C19 inhibitor or a moderate CYP3A4 inhibitor. Avoid initiation of concomitant weak CYP2C19 and moderate CYP3A4 inhibitors in patients who are on stable treatmentthe withlowest 2.5recommended mgdose of CAMZYOS because a lower dose is not available [see Dosage and Administration (2.2)]. For short-term use (e.g., 1 week), interrupt CAMZYOS for the duration of treatment with a weak inhibitor of CYP2C19 or a moderate inhibitor of CYP3A4. CAMZYOS may be reinitiated at the previous dose immediately on discontinuation of concomitant therapy.
Moderate CYP2C19 Inhibitors or Strong CYP3A4 Inhibitors
Clinical Impact | Concomitant use with a moderate CYP2C19 inhibitor or a strong CYP3A4 inhibitor increases mavacamten exposure, which may increase the risk of adverse drug reactions [see Warnings and Precautions (5.2)]. Discontinuing use of a moderate CYP2C19 inhibitor or strong CYP3A4 inhibitor after long-term concomitant use may decrease mavacamten exposure, which may reduce CAMZYOS’ efficacy [see Clinical Pharmacology (12.3)].
Prevention or Management | Initiate CAMZYOS at a starting dosageone ofdose 2.5below mgthe orallyrecommended oncestarting dailydose in patients who are on stable therapy with a moderate CYP2C19 inhibitor or a strong CYP3A4 inhibitor. Reduce dose of CAMZYOS to the next lower daily (mg) dose level ([i.e., 15 mg to 10 mg,; 10 mg to 5 mg, or; 5 mg to 2.5 mg; or 2.5 mg to 1 mg (pediatric)] in patients who are on CAMZYOS and intend to initiate a moderate CYP2C19 inhibitor or a strong CYP3A4 inhibitor. Avoid initiation of concomitant moderate CYP2C19 and strong CYP3A4 inhibitors in patients who are on stable treatmentthe withlowest 2.5recommended mgdose of CAMZYOS because a lower dose is not available [see Dosage and Administration (2.2)]. An increase in dose of CAMZYOS may be needed if the moderate inhibitor of CYP2C19 or strong inhibitor of CYP3A4 is discontinued after long-term concomitant use. Monitor for new or worsening symptoms. For short-term use (e.g., 1 week), interrupt CAMZYOS for the duration of treatment with a moderate inhibitor of CYP2C19 or a strong inhibitor of CYP3A4. CAMZYOS may be reinitiated at the previous dose immediately on discontinuation of concomitant therapy.
7.2 Potential for CAMZYOS to Affect Plasma Concentrations of Other Drugs
7 unchanged lines

Use in specific populations

Changed85 words added, 1 removed
13 unchanged lines
When mavacamten was administered orally to pregnant rabbits (0.6 to 2.0 mg/kg/day) during the period of organogenesis, fetal malformations (visceral and skeletal) were increased at doses of 1.2 mg/kg/day and higher, with similar plasma exposure at 1.2 mg/kg/day as in humans at the MRHD. Visceral findings consisted of malformations of the great vessels (dilatation of pulmonary trunk and/or aortic arch). Skeletal malformations consisted of higher incidences of fused sternebrae at ≥1.2 mg/kg/day. Plasma exposure (AUC) at the no-effect dose for embryo-fetal development in rabbits is 0.4 times the exposure in humans at the MRHD.
In a pre/postnatal development study, mavacamten was administered orally to pregnant rats (0.3, to 1.5 mg/kg/day) from gestation Day 6 to lactation/post-partum Day 20. No adverse effects were observed in the dams or offspring exposed daily from before birth (in utero) through lactation. The no-observed-adverse-effect level (NOAEL) was 1.5 mg/kg/day (the highest dosage level tested), with similar exposure (AUC) as in humans at the MRHD.
8.2 Lactation
9 unchanged lines
8.4 Pediatric Use
The safety and effectiveness of CAMZYOS for the treatment of symptomatic obstructive HCM have been established in pediatric patients weighing 30 kg or more. Use of CAMZYOS is supported by evidence from an adequate and well-controlled trial in adults, with additional pharmacokinetic, pharmacodynamic and safety data from a randomized, double-blind, placebo-controlled, multicenter study, SCOUT-HCM, in pediatric patients aged 12 to less than 18 years of age [see Adverse Reactions (6.1) and Clinical Studies (14)].
The safety and effectiveness of CAMZYOS have not been established in pediatric patients weighing less than 30 kg.
8.5 Geriatric Use
Clinical trials included 319 adult patients dosed with CAMZYOS, 119 of whom were 65 years of age or older (37.3%), and 25 of whom (7.8%) were age 75 years or older. Safety, effectiveness, and pharmacokinetics were similar between patients ≥65 years and younger patients.
8.6 Hepatic Impairment
1 unchanged line

Overdosage

Changed2 words added, 11 removed
8 unchanged lines
•Provide medically supportive measures to maintain hemodynamic stability and monitor left ventricular function.
•Consider administering activated charcoal (pediatric dose is 1 g/kg; adult dose is 50 g) within 2 hours of ingestion in addition to other supportive measures. The benefit of activated charcoal is negligible after 6 hours post ingestion [see Clinical Pharmacology (12.3)].
•Consider contacting the Poison Help line (1-800-222-1222) or a medical toxicologist for additional overdose management recommendations.

Description

Changed17 words added, 14 removed
3 unchanged lines
The structural formula of mavacamten is:
Mavacamten is a white to off-white powder that is practically insoluble in water and aqueous buffers at pH 2-10, sparingly soluble in methanol and ethanol, and freely soluble in DMSOdimethyl sulfoxide and NMPN-methyl-2-pyrrolidone.
CAMZYOS is supplied as immediate release Size 2 hard gelatin capsules, containing 1 mg, 2.5 mg, 5 mg, 10 mg, or 15 mg of mavacamten per capsule as active ingredient and the following inactive ingredients: croscarmellose sodium, hypromellose, magnesium stearate (non-bovine), mannitol, and silicon dioxide. The capsule shell contains black edible ink, black ironferric oxide, gelatin, red, ironferric oxide yellow, titaniumferrosoferric dioxideoxide, andgelatin, yellowand irontitanium oxidedioxide.

Clinical pharmacology

Changed269 words added, 1 removed
4 unchanged lines
Left Ventricular Ejection Fraction and Left Ventricular Outflow Tract Obstruction
Adult Patients
In the EXPLORER-HCM trial [see Clinical Studies (14)], patients achieved reductions in mean resting and provoked (Valsalva) LVOT gradient by Week 4 which were sustained throughout the 30-week trial. At Week 30, the mean (SD) changes from baseline in resting and Valsalva LVOT gradients were -39 (29) mmHg and -49 (34) mmHg, respectively, for the CAMZYOS group and -6 (28) mmHg and -12 (31) mmHg, respectively, for the placebo group. The reductions in Valsalva LVOT gradient were accompanied by decreases in LVEF, generally within the normal range. Eight weeks after discontinuation of CAMZYOS, mean LVEF and Valsalva LVOT gradients were similar to baseline.
Pediatric Patients
In the SCOUT-HCM trial [see Clinical Studies (14)], patients achieved reductions in mean resting and provoked (Valsalva) LVOT gradient: at Week 28, the mean (SD) changes from baseline in resting and Valsalva LVOT gradients were -41 (35) mmHg and -49 (43) mmHg, respectively, for the CAMZYOS group and 5.3 (23) mmHg and -1.8 (38) mmHg, respectively, for the placebo group.
Cardiac Structure
In the EXPLORER-HCM trial [see Clinical Studies (14)], echocardiographic measurements of cardiac structure showed a mean (SD) reduction from baseline at Week 30 in left ventricular mass index (LVMI) in the mavacamten group (-7.4 [17.8] g/m2) versus an increase in LVMI in the placebo group (8.9 [15.3] g/m2). There was also a mean (SD) reduction from baseline in left atrial volume index (LAVI) in the mavacamten group (-7.5 [7.8] mL/m2) versus no change in the placebo group (-0.1 [8.7] mL/m2). The clinical significance of these findings is unknown.
Cardiac Biomarkers
Adult Patients
In the EXPLORER-HCM trial [see Clinical Studies (14)], reductions in a biomarker of cardiac wall stress, NT-proBNP, were observed by Week 4 and sustained through the end of treatment. At Week 30 compared with baseline, the reduction in NT-proBNP after mavacamten treatment was 80% greater than for placebo (proportion of geometric mean ratio between the two groups, 0.20 [95% CI: 0.17, 0.24]).
In the VALOR-HCM trial [see Clinical Studies (14)], a reduction in NT-proBNP was observed by Week 8 and sustained throughout treatment. At Week 16 compared with baseline, the reduction in NT-proBNP after mavacamten treatment was 67% greater than for placebo (proportion of geometric mean ratio between the two groups, 0.33 [95% CI: 0.27, 0.42]). At Week 16 compared with baseline, a reduction in cardiac troponin I after mavacamten treatment was 47% greater than for placebo (proportion of geometric mean ratio between the two groups, 0.53 [95% CI: 0.41, 0.70]).
Pediatric Patients
In the SCOUT-HCM trial [see Clinical Studies (14)], a reduction in NT-proBNP was observed. At Week 28 compared with baseline, the reduction in NT-proBNP after mavacamten treatment was 77% greater than for placebo (proportion of geometric mean ratio between the two groups, 0.23 [95% CI: 0.14, 0.37]). At Week 28 compared with baseline, a reduction in cardiac troponin I after mavacamten treatment was 63% greater than for placebo (proportion of geometric mean ratio between the two groups, 0.37 [95% CI: 0.23, 0.60]).
The clinical significance of the NT-proBNP and troponin findings is unknown.
Cardiac Electrophysiology
In healthy adult volunteers receiving multiple doses of CAMZYOS, a concentration-dependent increase in the QTc interval was observed at doses up to 25 mg once daily. No acute QTc changes have been observed at similar exposures during single-dose studies. The mechanism of the QT prolongation effect is not known.
A meta-analysis across clinical studies in HCM patients does not suggest clinically relevant increases in the QTc interval in the therapeutic exposure range. In HCM, the QT interval may be intrinsically prolonged due to the underlying disease, in association with ventricular pacing, or in association with drugs with potential for QT prolongation commonly used in the HCM population. The effect of coadministration of CAMZYOS with other QT-prolonging drugs or in patients with potassium channel variants resulting in a long QT interval have not been characterized.
12.3 Pharmacokinetics
Mavacamten exposure increases dose proportionally following multiple once-daily doses of 1 mg to 15 mg. At the same dose level of CAMZYOS, 170% higher exposures of mavacamten are observed in patients with HCM compared to healthy subjects. Mavacamten accumulation is approximately 100% for Cmax and approximately 600% for AUC in CYP2C19 normal metabolizers (NMs). The accumulation is dependent upon the CYP2C19 metabolism status with the largest accumulation occurring in CYP2C19 poor metabolizers (PMs). At steady-state, the peak-to-trough mavacamten plasma concentration ratio with once daily dosing is approximately 1.5.
Absorption
14 unchanged lines
Mavacamten exposures (AUC) increased up to 220% in patients with mild (Child-Pugh A) or moderate (Child-Pugh B) hepatic impairment. The effect of severe (Child-Pugh C) hepatic impairment is unknown.
Pediatric Patients
The pharmacokinetics of mavacamten were evaluated in pediatric patients with obstructive HCM aged 12 to <18 years old who received once-daily oral doses of 1 mg to 15 mg of mavacamten. The pharmacokinetics of mavacamten in pediatric patients aged 12 to <18 years are comparable to those in adult patients. Pediatric patients aged 12 to <18 years and weighing 30 to <45 kg who receive the recommended starting dose of 2.5 mg daily are expected to have comparable exposure to adults who receive the recommended adult starting dose of 5 mg daily.
Drug Interactions
18 unchanged lines

Clinical studies

Changed575 words added, 22 removed
14 CLINICAL STUDIES
Adults
EXPLORER-HCM
The efficacy of CAMZYOS was evaluated in EXPLORER-HCM (NCT-03470545) a Phasephase 3, double-blind, randomized, placebo-controlled, multicenter, international, parallel-group trial in 251 adults with symptomatic NYHA class II and III obstructive HCM, LVEF ≥55%, and LVOT peak gradient ≥50 mmHg at rest or with provocation.
Patients on dual therapy with beta blocker and calcium channel blocker treatment or monotherapy with disopyramide or ranolazine were excluded. Patients with a known infiltrative or storage disorder causing cardiac hypertrophy that mimicked obstructive HCM, such as Fabry disease, amyloidosis, or Noonan syndrome with left ventricular hypertrophy, were also excluded.
12 unchanged lines
Change from baseline pVO2 ≥3 mL/kg/min and NYHA not increased | 29 (23%) | 14 (11%) | 13% (3, 22) |
A range of demographic characteristics, baseline disease characteristics, and baseline concomitant medications were examined for their influence on outcomes. Results of the primary analysis consistently favored CAMZYOS across all subgroups analyzed (Figure 45).
Figure 45: Subgroup Analysis of the Primary Composite Functional Endpoint
The dashed vertical line represents the overall treatment effect and the solid vertical line (no effect) indicates no difference between treatment groups. Note: The figure above presents effects in various subgroups, all of which are baseline characteristics. The 95% confidence limits that are shown do not take into account the number of comparisons made and may not reflect the effect of a particular factor after adjustment for all other factors. Apparent homogeneity or heterogeneity among groups should not be over-interpreted.
1 unchanged line
Secondary endpoints
The treatment effects of CAMZYOS on LVOT obstruction, functional capacity, and health status were assessed by change from baseline through Week 30 in post-exercise LVOT peak gradient, change in pVO2, proportion of patients with improvement in NYHA class, Kansas City Cardiomyopathy Questionnaire-23 (KCCQ-23) Clinical Summary Score (CSS), and Hypertrophic Cardiomyopathy Symptom Questionnaire (HCMSQ) Shortness of Breath (SoB) domain score. At Week 30, patients receiving CAMZYOS had greater improvement compared to the placebo group across all secondary endpoints (Table 3, Figure 56, Figure 67, Table 4, and Figures 78-1011).
Table 3: Change from Baseline to Week 30 in Post-Exercise LVOT Gradient, pVO2, and NYHA Class
3 unchanged lines
Number (%) with NYHA Class improved ≥1 | 80 (65%) | 40 (31%) | 34% (22%, 45%) | <0.0001
Figure 56: Cumulative Distribution of Change from Baseline to Week 30 in LVOT Peak Gradient
Figure 67: Cumulative Distribution of Change from Baseline to Week 30 in pVO2
Table 4: Change from Baseline to Week 30 in KCCQ-23 CSS and HCMSQ SoB Domain
6 unchanged lines
HCMSQ SoB‡ | n=108 5 (3) | n=109 5 (3) | -3 (3) | -1 (2) | -2 (-2, -1) p<0.0001
Figure 78 shows the time course for changes in KCCQ-23 CSS. Figure 89 shows the distribution of changes from baseline to Week 30 for KCCQ-23 CSS.
Figure 78: KCCQ-23 Clinical Summary Score: Mean Change from Baseline Over Time
Figure 89: KCCQ-23 Clinical Summary Score: Cumulative Distribution of Change from Baseline to Week 30
Figure 910 shows the time course for changes in HCMSQ SoB. Figure 1011 shows the distribution of changes from baseline to Week 30 for HCMSQ SoB.
Figure 910: HCMSQ Shortness of Breath Domain: Mean Change from Baseline Over Time
Figure 1011: HCMSQ Shortness of Breath Domain: Cumulative Distribution of Change from Baseline to Week 30
VALOR-HCM
The efficacy of CAMZYOS was evaluated in VALOR-HCM (NCT-04349072), a Phasephase 3, double-blind, randomized, 16-week, placebo-controlled trial in 112 patients (mean age of 60 years; 51% men; 93% ≥NYHA class III) randomized 1:1 to receive treatment with CAMZYOS or placebo. At baseline, all patients had symptomatic obstructive HCM and were SRT eligible.
Patients with severely symptomatic drug-refractory obstructive HCM (including 33% on any combination of beta-blocker, calcium channel blocker and/or disopyramide; 20% were on disopyramide alone or in combination with other treatment), and NYHA class III/IV or class II with exertional syncope or near syncope, were included in the study. Patients were required to have LVOT peak gradient ≥50 mmHg at rest or with provocation, and LVEF ≥60%. Patients must have been referred or under active consideration within the past 12 months for SRT and actively considering scheduling the procedure.
19 unchanged lines
KCCQ-23 PL, mean (SD) | 10 (19) | 2 (17) | 10 (5, 16) |
Figure 1112 shows the time course for changes in KCCQ-23 CSS. Figure 1213 shows the distribution of changes from baseline to Week 16 for KCCQ-23 CSS.
Figure 1112: KCCQ-23 Clinical Summary Score: Mean Change from Baseline Over Time
Figure 1213: KCCQ-23 Clinical Summary Score: Cumulative Distribution of Change from Baseline to Week 16 The figure displays the cumulative percentage of patients achieving a certain level of response.
Pediatric Patients
SCOUT-HCM
The efficacy of CAMZYOS was evaluated in SCOUT-HCM (NCT-06253221), a phase 3, double-blind, randomized, placebo-controlled, multicenter, international trial in 44 pediatric patients (23 mavacamten, 21 placebo), aged 12 years to <18 years who weighed ≥ 35 kg with symptomatic obstructive HCM, NYHA class II and III, LVEF ≥60%, and LVOT peak gradient ≥50 mmHg at rest or with provocation.
Background therapy (e.g., beta-blocker, calcium channel blocker, disopyramide, or combinations thereof) was allowed. Key exclusion criteria included phenocopy disease or multiple organ system malformation syndrome resulting in myocardial hypertrophy not related to sarcomere dysfunction and hypercontractility (e.g., Noonan syndrome, Pompe disease, Fabry disease, Friedreich ataxia, or Danon disease).
Patients were randomized 1:1 to receive either CAMZYOS (starting dose of 2.5 mg for body weight 35 to <45 kg, 5 mg for body weight ≥45 kg) or placebo once daily for 28 weeks. Randomization was stratified by age (12 ≤ to < 15 years, 15 ≤ to < 18 years) and beta-blocker use at baseline (yes/no).
Doses were individually titrated based on clinical echocardiogram parameters obtained at scheduled visits within protocol-defined windows in single dose increments (1 mg, 2.5 mg, 5 mg, 10 mg, or 15 mg) up to a maximum dose of 15 mg once daily. Down-titration occurred based on echocardiogram at approximately Weeks 4 and 8 if Valsalva LVOT gradient was <20 mmHg and LVEF was ≥50%. Up-titration occurred based on echocardiogram at approximately Weeks 11 and 23 if Valsalva LVOT gradient was ≥30 mmHg and LVEF was ≥55%. At Week 28, in the CAMZYOS group, 39% of patients were on the 15 mg dose, 30% were on the 10 mg dose, 17% were on the 5 mg dose, 9% were on the 2.5 mg dose, and 4% were on the 1 mg dose.
At baseline, mean age of the patients was 15 years with 50% aged 12 to < 15 years, 30% were females, 68% White, 7% Black, 5% Asian, and 20% unknown or not reported, 84% were NYHA class II, 16% were NYHA class III, 84% were on a beta-blocker, 11% were on a calcium channel blocker, 20% were on disopyramide, and 25% were on at least 2 HCM treatments. Baseline demographic characteristics were largely balanced between CAMZYOS and placebo arms.
Primary endpoint
The primary efficacy endpoint was change from baseline in Valsalva LVOT gradient at Week 28. A mean (SD) change in the Valsalva LVOT gradient at Week 28 of -49.4 (42.6) mmHg and -1.8 (37.8) mmHg was observed in the CAMZYOS versus placebo group, respectively, with a statistically significant least squares mean difference of -48.0 mmHg; 95% CI: -67.7, -28.3; p<0.0001 favoring CAMZYOS. The primary endpoint results favored CAMZYOS across all prespecified subgroup analyses including age, sex, and race.
CAMZYOS reduced resting and Valsalva LVOT gradient and improved functional capacity and symptoms in adult patients. Similarly, CAMZYOS reduced resting and Valsalva LVOT gradient in pediatric patients ≥ 35 kg. The pharmacokinetics of mavacamten in pediatric patients ≥ 30 kg are comparable to those in adult patients [see Clinical Pharmacology (12.3)]. Based on these data, CAMZYOS is expected to improve functional capacity and symptoms in pediatric patients with symptomatic obstructive HCM weighing ≥ 30 kg.

How supplied

Changed8 words added
16 HOW SUPPLIED/STORAGE AND HANDLING
CAMZYOS® is supplied as immediate release Size 2 hard gelatin capsules containing 1 mg, 2.5 mg, 5 mg, 10 mg, or 15 mg of mavacamten. White opaque capsule bodies are imprinted with “Mava”, and the opaque cap is imprinted with the strength. The capsule contains white to off-white powder. CAMZYOS capsules are available in bottles of 30 capsules, as listed in the table below:
Strength | Capsule Cap | NDC Number
1 mg | White | 73625-110-11
2.5 mg | Light purple | 73625-111-11
5 unchanged lines

Medication guide

Changed27 words added, 15 removed
5 unchanged lines
o fatigue | o rapid weight gain
• The risk of heart failure is also increased when CAMZYOS is taken with certain other medicines. Tell your healthcare provider about the medicines you take, both prescribed and obtained over-the-counter, before and during treatment with CAMZYOS. • Because of the serious risk of heart failure, CAMZYOS is only available through a restricted program called the CAMZYOS Risk Evaluation and Mitigation Strategy (REMS) Program. oYour healthcare provider must be enrolled in the CAMZYOS REMS Program in order for you to be prescribed CAMZYOS. oBefore you take CAMZYOS, you must enroll in the CAMZYOS REMS Program. Talk to your healthcare provider about how to enroll in the CAMZYOS REMS Program. You will be given information about the program when you enroll. oBefore you take CAMZYOS, your healthcare provider and pharmacist will make sure you understand how to take CAMZYOS safely, which will include returning for echocardiograms when advised by your healthcare provider. CAMZYOS can only be dispensed by a certified pharmacy that participates in the CAMZYOS REMS Program. Your healthcare provider can give you information on how to find a certified pharmacy. You will not be able to get CAMZYOS at a local pharmacy. oIf you have questions about the CAMZYOS REMS Program, ask your healthcare provider, go to www.CAMZYOSREMS.com, or call 1-833-628-7367. See “What are the possible side effects of CAMZYOS?” for information about side effects.
What is CAMZYOS? CAMZYOS is a prescription medicine used to treat adults and children weighing 66 pounds (30 kg) or more with symptomatic obstructive hypertrophic cardiomyopathy (HCM). CAMZYOS may improve your symptoms and your ability to be active. It is not known if CAMZYOS is safe and effective in children weighing less than 66 pounds (30 kg).
Before taking CAMZYOS, tell your healthcare provider about all of your medical conditions, including if you: •are pregnant or plan to become pregnant. CAMZYOS may harm your unborn baby. Tell your healthcare provider right away if you become pregnant or think you may be pregnant during treatment with CAMZYOS. You may also report your pregnancy by calling Bristol-Myers Squibb at 1-800-721-5072 or www.bms.com. If you are a female and able to become pregnant: oYour healthcare provider will do a pregnancy test before you start treatment with CAMZYOS. oYou should use effective birth control (contraception) during treatment with CAMZYOS and for 4 months after your last dose of CAMZYOS. oCAMZYOS may reduce how well some hormonal birth control works. Talk to your healthcare provider about the use of effective forms of birth control during treatment with CAMZYOS. •are breastfeeding or plan to breastfeed. It is not known if CAMZYOS passes into your breast milk. Talk to your healthcare provider about the best way to feed your baby during treatment with CAMZYOS. Before and during CAMZYOS treatment, tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Taking CAMZYOS with certain medicines or grapefruit juice may cause heart failure. Do not stop or change the dose of a medicine or start a new medicine without telling your healthcare provider. Especially tell your healthcare provider if you: •Take over-the-counter medicines such as omeprazole (for example, Prilosec), esomeprazole (for example, Nexium), or cimetidine (for example, Tagamet). •Take other medicines to treat your obstructive HCM disease. •Develop an infection.
3 unchanged lines
General information about the safe and effective use of CAMZYOS. Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use CAMZYOS for a condition for which it was not prescribed. Do not give CAMZYOS to other people, even if they have the same symptoms you have. It may harm them. You can ask your healthcare provider or pharmacist for information about CAMZYOS that is written for health professionals.
What are the ingredients in CAMZYOS? Active ingredient: mavacamten Inactive ingredients: croscarmellose sodium, hypromellose, magnesium stearate (non-bovine), mannitol, and silicon dioxide. The capsule contains black ironferric oxide, gelatin, red, ironferric oxide yellow, titaniumferrosoferric dioxideoxide, andgelatin yellowand irontitanium oxidedioxide. Marketed by: Bristol-Myers Squibb Company Princeton, NJ 08543 USA CAMZYOS® is a trademark of MyoKardia, Inc., a Bristol Myers Squibb company. For more information, go to www.CAMZYOS.com or call 1-800-721-5072.
This Medication Guide has been approved by the U.S. Food and Drug Administration. | Revised: 04/2025September 2026

CAMZYOS 1 mg Label

Changed20 words added, 20 removed
CAMZYOS 51 mg Label
NDC 73625-112-11
Rx only
CAMZYOS™
(mavacamten)
capsules
5 mg
Dispense the enclosed Medication Guide to each patient.
NDC 73625-110-11 Rx only CAMZYOS ® (mavacamten) capsules 1 mg Dispense the enclosed Medication Guide to each patient.
Recommended Dosage: See Prescribing Information
4 unchanged lines

CAMZYOS 5 mg Label

Changed3 words added, 3 removed
CAMZYOS 105 mg Label
NDC 73625-113112-11
Rx only
2 unchanged lines
capsules
105 mg
Dispense the enclosed Medication Guide to each patient.
5 unchanged lines

CAMZYOS 10 mg Label

Changed3 words added, 3 removed
CAMZYOS 1510 mg Label
NDC 73625-114113-11
Rx only
2 unchanged lines
capsules
1510 mg
Dispense the enclosed Medication Guide to each patient.
5 unchanged lines

CAMZYOS 15 mg Label

New section50 words added
CAMZYOS 15 mg Label
NDC 73625-114-11
Rx only
CAMZYOS™
(mavacamten)
capsules
15 mg
Dispense the enclosed Medication Guide to each patient.
Recommended Dosage: See Prescribing Information
Keep out of reach of children.
Do not use if inner seal bottle is broken or missing.
30 Capsules
Bristol Myers Squibb

Unchanged: Boxed warning, Nonclinical toxicology, Patient counseling information, CAMZYOS 2.5 mg Label.

Every version

9 versions of set 669c936b-3ee6-4e36-8a22-79dd11b1255b, newest first.
VersionPublished on DailyMedCompareSPL file
9Oct 12, 2026Shown belowDownload .zip
8May 1, 2025With version 7Download .zip
7Jul 9, 2024With version 6Download .zip
6May 13, 2024With version 5Download .zip
5Jun 29, 2023With version 4Download .zip
4Nov 16, 2022With version 3Download .zip
3Oct 14, 2022With version 2Download .zip
2Aug 11, 2022With version 1Download .zip
1May 11, 2022First versionDownload .zip

Read an SPL file

Open an SPL label file

Drop a Structured Product Labeling .xml file, or the .zip DailyMed downloads, to read it as a label. It is read in this browser tab and not uploaded.

Read in this browser tab; nothing is uploaded.

Versions and label text from DailyMed's SPL web services; a version's text is read from its SPL file, so it matches what DailyMed shows. Recent safety-related changes from FDA's Safety-related Labeling Changes database, which covers NDAs and CDER biologics, not generics. Lists refresh daily. DailyMed, National Library of Medicine

About label change history

How to read a comparison

Sections that changed come first, in the order a reviewer reads a label: boxed warning, recent major changes, indications, dosage, contraindications, warnings and precautions, adverse reactions, then the rest. Each shows the changed lines with one unchanged line either side; longer unchanged stretches are folded into a count. Table rows read left to right with cells separated by a bar.

The comparison covers the label text. Images, product data (NDC codes, ingredients, packaging) and formatting are not compared.

Which label is shown

A drug can have several labels: one per brand-name application (Ozempic, Wegovy and Rybelsus are three), and copies from repackagers. For each NDA or BLA the page takes the DailyMed set with the most versions, which is the application holder's. Generic labels are left out; they follow the brand's label.

Frequently asked questions

Where do the versions come from?
DailyMed, the National Library of Medicine's library of labels in Structured Product Labeling (SPL) format. Each time a company submits a revised label, DailyMed publishes it as a new version of the same set and keeps the old ones.
Is a new version a new FDA approval?
Not always. Companies also submit new versions for changes that need no FDA approval first, such as a new address, a new package size or a corrected typo. Safety changes FDA approved are listed in its Safety-related Labeling Changes database, linked below.
Why does the published date differ from the label's revised date?
The published date is when DailyMed posted the version. The label's own revised date, at the end of the highlights, is when the company revised the text, usually a few days to weeks earlier.
How is the comparison made?
Each section is matched by its standard LOINC code, then split into headings, paragraphs, list items and table rows. Lines are aligned with a longest-common-subsequence diff; a removed and an added line that share at least half their words are shown as one edited line with the changed words marked. Curly quotes, dash styles and spacing are ignored.
Is my SPL file uploaded?
No. A file you drop on this page is read in your browser tab and never sent to Arca.
Esc

Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.